Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looking good INNV! §
American CareSource Holdings, Inc. to Transfer Its Ancillary Network Business to HealthSmart
American CareSource Holdings, Inc. (OTCQB:GNOW) (the "Company"), an urgent and primary care company operating under the name GoNow Doctors ("GoNow"), announced today that it has entered into an asset purchase agreement with HealthSmart Preferred Care II, L.P. (“HealthSmart Preferred Care”), a subsidiary of HealthSmart Holdings, Inc. Under the terms of the asset purchase agreement, HealthSmart Preferred Care has agreed to purchase certain specified assets and contracts from the Company and from two of its wholly-owned subsidiaries related to the Company’s ancillary network business (the “Transaction”). The Transaction does not include the Company’s urgent care and primary care business and excludes other mutually agreed assets and liabilities.
As we previously announced, we commenced efforts in the fourth quarter of 2015 to sell our ancillary network business to HealthSmart Preferred Care as part of our focus on our urgent and primary care business and our transition away from our legacy ancillary network business. The Transaction involves the transfer of the clients and medical providers of the network and certain related liabilities. The Transaction is subject to customary closing conditions, but we anticipate the Transaction will close in the third quarter of this year.
About American CareSource Holdings, Inc.
American CareSource Holdings, Inc. owns and manages a chain of 10 urgent and primary care centers operating under the tradenames Medac and GoNow Doctors and owns an ancillary services network that provides ancillary healthcare services through its nationwide provider network. GoNow's stock trades on the OTC Markets OTCQB under the ticker "GNOW."
About HealthSmart
For more than 40 years, HealthSmart Holdings, Inc. and its subsidiaries have offered a wide array of customizable and scalable health plan solutions for self-funded employers. HealthSmart’s comprehensive service suite addresses individual health from all angles. This includes claims and benefits administration, provider networks, pharmacy benefit management services, business intelligence, onsite employer clinics, care management, a variety of health and wellness initiatives and web-based reporting. The Company's headquarters is in Irving, Texas, with regional hubs throughout the country. HealthSmart’s mission is to improve member health and reduce healthcare costs.
Contact:
Adam Winger
Chief Executive Officer
GoNow Doctors
Tel: 205.250.8381
Thomas Kelly
Chief Executive Officer
HealthSmart
Tel: 800.687.0500
§
Got most of the 34s filled today. I moved down...it moved up. Should have left them.
GO RXMD...oh yeah, a bunch of $$$$$$s
§
And there you go. Papajohn takes control. What kind of offer will he give? Fair value is .48
GLTA
§
It's the maple syrup in the coffee!
Hmmmm...Genisis...Sex pistols...no, I got it...
Can't recall a stock that has thrown so much fluff at the wire, and it's predictably hit zero effect level. The extra cash is coming from sales though, and while the co is diluting, evidenced by the outside trades, this CEO has done this before and is following a proven business plan.
Bottom feeding can still pay off well here but the volatility is going to dry up. Longer term I think this is a good investment. A structure adjustment (R/S) and move to exchange listing and the BOD will sell at a handsome premium, IMO.
headsortails2066: Debt pay down news an obvious precursor to your well-presumed 75% increase in sales PR coming for next Q.
§
I don't think the charts mean much for development stage biotechs. Blue chips with known fundamentals and predictable catalysts adhere to patterns better. I tend to swing trade based on volume trends. Larger volume can make for 30 - 40¢ swings in AVXL. Light volume and maybe 20¢ can be done, but that is still great volatility compared to stocks that trade on the 100th of a penny spread all day.
123tom is very good at calling levels and they usually correspond to the 20, 30, 40¢ swings I'm talking about. He is a better peep to ask and he has a study group board.
However, since we are heading for Russell inclusion I think the price will appreciate through July due to benchmark buying. I am now plotting AVXL against the IWV (and little demon girl, as usual) and I think we will close the gap some, there.
I would call 5.50 breakout area.
GLTA
§
The blue urine blew the study blinding, too. Now they are using 4% LMTX in the placebo to mask it. Said no other type of coloring was comparatively useful...quite odd, but not unheard of. The 100mg dose in the P2 reacted with the gelatin capsule and caused problems. The new formula is tablet.
"PubMed contains no publications on Rember’s preclinical or clinical development, nor on LMTX. Wischik’s team has not yet submitted the Phase 2 AD trial results to a peer-reviewed journal. “Clinicians in general don’t believe Phase 2 data in AD anymore, and publishing won’t make any difference. All they are going to believe are Phase 3 results,” Wischik told Alzforum."
http://www.alzforum.org/news/research-news/will-tau-drug-show-its-true-colors-phase-3-trials
I am much more interested in the Lu 25-109, since it seems the most structurally related to A2-73 but was terminated due to AEs at effective doses.
http://www.ncbi.nlm.nih.gov/pubmed/10668706
Much of the info on the development steps to Anavex' compounds is further clarified by reading about these past failures. Regardless of the approval outcome, this receptor chemistry science is crucial to modern medicine.
§
Nice work Mikesc! Now, if you could get them to explain how A2-73 differs from Alvameline (Lu 25-109)...that would be great.
https://en.wikipedia.org/wiki/Alvameline
https://www.researchgate.net/publication/13602158_In_vivo_muscarinic_cholinergic_mediated_effects_of_Lu_25-109_a_M1_agonist_and_M2M3_antagonist_in_vitro
http://www.sciencedirect.com/science/article/pii/S0024320597010874
Is the lower dosage of A2-73, which has a much longer duration and half-life, not producing the extreme chollergenic side effects while providing a disease-modifying effect over an extended time?
Dr V, et al certainly seem to have expounded on the research in their development of our compounds.
http://www.ncbi.nlm.nih.gov/pubmed/12714934
Again, the specifics of allosteric, selectivity, affinity, heterodimerization, sodium channels, etc seem to be (perhaps) the keys to making compounds work as intended (hypothesized).
I continually find support for the Anavex thesis as well as a particularly intriguing Cinderella story. How anybody could critisize the CEO is beyond me. Knight in shining armor is more like it...for the little redheaded princess!
§
In support of that post I must link to some good reading. I'm a big fan of the ALZForum
http://www.alzforum.org/therapeutics/rember-tm
http://www.alzforum.org/news/research-news/will-tau-drug-show-its-true-colors-phase-3-trials
http://www.ncbi.nlm.nih.gov/pubmed/9794144
This excellent paper illustrates how A2-73 being an M1 agonist and M3 antagonist may decrease the phosphorylation of tau upstream from the MB hyper-phosphorylation prevention MOA. The modulating of S1 receptor to stabilize intra-cellular calcium levels may also keep the tau from becoming extra-cellular and phosphorylated in the first place:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683623/
TauRx is likely eager to put their compound(s) before the FDA ahead of Anavex. Their data supports the Anavex thesis, where as Anavex' may render theirs unnecessary, so we might be the "stiffer" of the competition. Our dose max right now is 50mg once daily, while LMTX is 60mg three times daily and causes nausea if not taken with food and diarrhea.
Saftey will be the key, and that being the primary objective of the 2 year extension tells me that the drug is most obviously working.
andthentheres3-71!
§
Not really "stiff". Their compounds are aggregation inhibitors, basically methylene blue, and the A2-73 preclinical studies showed upstream synergy with MB. The patent 9,180,106
"Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anti-cancer activity" covers A2-73 and MB in cancerous melanoma.
Could actually turn out to be highly synergistic.
§
F1ash: A great reminder. Thank you!
Yes, seems prudent considering the circumstances. At minimal shareholder expense...of course!
§
I doubt the conference refuses anybody willing to pay the fee. There is over 600 presentations. The guidelines probably have more to do with presenting current and unpublished scientific info rather than 'undisclosed info material to company share prices'.
The co would be wise to just PR the data before the conference with details to follow, IMO. I would like to see Dr Missling speak on the receptor science and leave the study data to the investigators.
§
LMAO Millsone! I believe this is the forth SCAS that Rosen will suffer dismissal on this year. As stated in the memorandum, even if the company paid for promotion there is nothing illegal or deceitful about that. Judge Furman won't waste 10 minutes deliberating this definitively frivolous litigation.
Re: AAIC details.
From TauRx on their P3 results:
"This Phase 3 programme is now coming to a conclusion but TauRx will not be making any public comments or issuing any statements about the individual trial results until the data from the final study to complete is available for analysis. The company currently plans to make an initial announcement of the results of the first two trials to complete at two presentations at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada on 27th July. Until then, TauRx believes it would be scientifically inappropriate to comment on results as data analysis is still ongoing."
http://taurx.com/clinical-trials/
These studies were completed late last year and are also still awaiting results. TauRx is basing an IPO on them, we might have a $150M secondary riding on ours.
Surely Missling will be speaking at AAIC. The poster title is the same as the original CTAD from last year with 'Dose Dependent' added. Looks placeholder to me.
§
Innovus Pharmaceuticals Announces Successful Top Line Results From RecalMax in Memory, Processing Speed and Thought Maintenance
SAN DIEGO, CA--(Marketwired - Jun 13, 2016) - Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB: INNV), a company focusing on the commercialization of over-the-counter ("OTC") and consumer products for men's and women's health, vitality and respiratory diseases, announced today that the Company's top line results from its RecalMax™ U.S. four month human survey use clinical trial in people with low memory and learning.
RecalMax™ use resulted in the following:
1. 115% increase in the recall of words and names
2. 49.5% increase in maintaining thoughts when distracted
3. 35% increase in processing speed
About the RCM-001 Use Survey Trial:
Method: Scores were assessed at initiation of trial, midpoint and conclusion. A five-point satisfaction scale was used. Satisfaction was summarized by combining scores from Mostly Satisfied, Satisfied, and Very Satisfied. Dissatisfaction was summarized using results from Dissatisfied and Very Dissatisfied.
Subjects: 72 patients completed the trial in the United States.
Age: Over 50% of participants who completed the trial were between the ages of 40-59. Over 70% were age 40 and older. This was true at baseline as well.
Regimen: One capsule twice a day for a total of 16 weeks.
Pursuant to these clinical trials, the data indicate that RecalMax™ was very well tolerated with no serious adverse events reported. The only minor events reported were dry mouth that was resolved by drinking 62 ounce of water daily and sleep disturbance, if taken in the late afternoon.
RecalMax™ is a proprietary oral low dose formulation of Arginine and Citrulline with the natural absorption enhancer Bioperine®. RecalMax™ was formulated to increase blood flow and nitric oxide production.
"We are thrilled about these results from the RecalMax™ use trial which confirms that positive activity of the product and opens an additional $3 billion market for the company," said Dr. Bassam Damaj, President & CEO of Innovus Pharma. "Memory and learning loss are major issues with diseases such as Alzheimer in aging population, and providing a natural product clinically tested to increase memory and learning to help brain health is a big step in managing the daily lives of the 5 million people in the U.S. and 26 million worldwide suffering from such conditions."
"Having clinical data showing improvement in memory and learning differentiates RecalMax™ from the rest of the products on the market and gives it the credibility needed to make a strong entry in to the market," added Dr. Damaj.
The Company expects to launch the product in Q3 2016.
About RecalMax™
RecalMax™ is a proprietary, novel oral dietary supplement to maximize nitric oxide's beneficial effects on brain health. RecalMax™ contains a patented formulation of low dose L-Arginine and L-Citrulline, in combination with the natural absorption enhancer Bioperine®.
www.recalmax.com
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and hopefully, eventually from FlutiCare™ OTC for Allergic Rhinitis for which an ANDA has been submitted to the U.S. Food and Drug Administration.
For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com.
Innovus Pharma's Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority, to successfully commercialize Vesele® and other products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
Contact Information
Contact:
Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
You're good, my friend.
§
Objective opinion is not nonsense. Frenchroll has proven themselves a valuable opinion in my eyes. Discourse has no place in discussion.
§
Likely ~86MM O/S. 68MM inside held and ~20MM float.
Channel sales are high. My local Walmart(s) Zestra Glide sales are a great indicator. Not publishing those #s any more.
GLTA
§
Innovus Pharma (INNV)'s Vesele Could Be the Best Complementary Product for Viagra and Cialis's $3.2 Billion Dollar Erectile Dysfunction Market
SAN DIEGO, CA--(Marketwired - Jun 9, 2016) - Innovus Pharma (OTCQB: INNV) -- The global erectile dysfunction drug market is expected to reach $3.2 billion USD by 2022 according to a new report by Grand View Research Inc. Male sexual dysfunction has become a multi-billion-dollar market fueled by sales of erectile dysfunction drugs like Viagra and Cialis. In fact, Pfizer Inc.'s Viagra surpassed $1 billion in sales during its first year despite having lower than usual third-party coverage. The drug has consistently surpassed $1 billion per year in sales since its launch and even briefly reached above the $2 billion mark back in 2012 despite growing competition.
To view the Pfizer's Viagra Revenue - Source: Statista chart please click here.
According to IMS data, Viagra accounted for over 47.0% of the total revenue in 2014. It is generally considered as the first line of treatment for erectile dysfunction. Brand loyalty and initial effectiveness are the major factors attributing for its large market share. Cialis (tadalafil) from Eli Lilly & Co. and Levitra (vardenafil) from Bayer AG are known to be the competitors for Viagra globally. Cialis (tadalafil) was approved in 2003 by the United States Food and Drug Administration as a prescription drug. Cialis is also known as "The Weekend Pill" owing to its 36-hour effectiveness.
North America constituted the largest share of approximately 55.0% in 2013 of the total erectile dysfunction market. Extension of patent exclusivity rights for Viagra (sildenafil citrate) in the U.S. till 2019 along with introduction of new erectile dysfunction drugs such as Zydena (udenafil) and Stendra/Spedra (avanafil) will be the major factors responsible for market growth during the forecast period.
Viagra and Cialis fall into the Phosphodiesterase type 5 inhibitors (PDE5) class of drugs and are currently the first line treatment for erectile dysfunction (ED), among others. PDE5 inhibitors work by increasing the blood flow to the penis through nitric oxide (NO) conversion therefore allowing a natural erection to take place. However, several published research shows that PDE5 treatments have high discontinuation rates. The study published by Carvalheira AA et al. in the highly reviewed Journal of Sexual Medicine shows that close to 40% of men on PDE5 inhibitors stop using the drugs due to loss of efficacy.
Innovus Pharmaceuticals' (OTCQB: INNV) Vesele®, currently on the U.S. market, is designed to maximize the benefits of NO. The product contains two amino acids: L-Citrulline and L-Arginine, plus a patented piperine extract called BioPerine®, that helps the body absorb these amino acids and results in higher NO production. Nitric Oxide relaxes blood vessels to allow for healthy blood flow throughout the body.
Innovus ran a 72 patient U.S. human survey use clinical trial over 16 weeks in people with low erectile dysfunction accompanying endpoints including: 1) erection hardness; 2) erection maintenance; 3) frequency of sexual encounters; and 4) desire for sexual encounters. The results announced by the company show that Vesele® use resulted in the following:
1. 49.5% increase in erection hardness
2. 44.5% increase in erection maintenance
3. 34.6% increase in desire for sexual activity
4. 34.1% increase the ability to satisfy the partner
5. 44% increase in overall satisfaction
Based on the results from Innovus' study and the similar mechanism of action of the PDE5 inhibitors and Vesele® it is conceivable that the combination of the two products might result in a higher blood flow and therefore better erections and clinical responses.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g) Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the U.S. and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA. For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com.
Looking Ahead
Innovus Pharmaceuticals plans to capitalize on the enormous market for erectile dysfunction with a clinically proven product with widespread distribution. Investors may want to keep an eye on the stock over the coming quarters as it expands awareness of Vesele and works to build out its other pipeline products. As it transitions to profitability, the company will likely attract the interest of a growing number of institutional investors.
For more information, visit the company's website at www.innovuspharma.com.
§
Nothing. Just bouncing off your shield of armor.
...weird scenes inside the gold mine...
NITE stepped in to accept ~120KK .20s....
JPJ going indirect already?
Ride the snake, he's old, and his skin is cold
The west is the best, the west is the best
Get here, and we'll do the rest
The blue bus is callin' us, the blue bus is callin' us
Driver, where you taken us
Papajohn where you taken us?
§
You buying that malarky?!!! Mr Renauer has no better straws to grasp at other than comparing the little redhead to the behemoth. Talk about trying to cover your arse! He'll be long as the day is short on the data confirmation.
What about the non-existent labs chocked full of overpaid corporate lab coats?
What makes Anavex a better buy?
Post #64763
Comment section, Cory?
§
Cat's out of the bag...
http://investorshub.advfn.com/boards/breakoutboards.aspx
§
A2-73 could be disease-modifying in MS. Biogen just failed there again. Maybe they should stop naming drugs ___mab!
http://www.bloomberg.com/news/articles/2016-06-07/biogen-plunges-after-ms-drug-fails-in-mid-stage-trial
http://www.nationalmssociety.org/For-Professionals/Clinical-Care/Managing-MS/Disease-Modification#section-5
http://bmcneurol.biomedcentral.com/articles/10.1186/s12883-016-0609-0
A2-73 acts as a S1 agonist and NMDA antagonist, just as DM, but without the serotonin reuptake inhibitor(SRI) properties. This may overcome the dose-limiting barrier of DM. An oral, well tolerated compound that can better DM's effects will be very promising in PBA for ALS and MS.
Friday, February 19, 2016
12:30 PM - 02:00 PM
Hyatt Regency New Orleans - Storyville Hall
Background: The sigma-1 receptor (S-1R) is an endoplasmic reticulum (ER) chaperone upregulated during ER stress; the receptor also regulates calcium homeostasis through its association with inositol triphosphate (IP3) at the ER membrane-associated mitochondrial interface. Activation of S-1R by a variety of agonists has neuroprotective effects both in vitro and in vivo. Dextromethorphan (DM) is a S-1R agonist as well as a weak N-methyl-D-aspartate receptor (NMDAR) antagonist, which in combination with quinidine sulfate is approved for treatment of pseudobulbar affect in multiple sclerosis (MS) and other neurologic diseases. We have reported that DM protects oligodendrocytes (OL) in vitro from the cytotoxic effects of staurosporine (inducer of apoptosis), glutamate (excitotoxicity), reactive oxygen species (ROS, induced by hydrogen peroxide, H202) and quinolinic acid (QA, a product of tryptophan indoleamine metabolism associated with inflammation) (Lisak et al. Glia, 2014).
Objectives:
To determine if another S-1R agonist might also have OL protective properties, which might be effective in progressive MS, we examined the effects of ANAVEX2-73 on protection of OL from these cytotoxic molecules. ANAVEX2-73 is a new clinical stage compound, which is chemically unrelated to DM, and a S-1R agonist, NMDAR antagonist, also targeting muscarinic receptors, currently in a Phase 2a trial in Alzheimer’s disease (Macfarlane et al. 2015 AAIC abstract).
Methods:
Glial cultures enriched in OL were prepared from newborn rat brain and cells identified by phenotypic markers (Lisak et al. Mult Scler, 2006). Cultures were incubated with various concentrations of ANAVEX2-73, 200 nanoM (nM)-200 microM, for 24 hours to assess cell death by trypan blue uptake. Since there was no toxicity noted at 200 nM, we then incubated cultures with staurosporine, glutamate, H2O2, QA or medium (control) and determined cell death.
Results:
ANAVEX2-73 reduced OL cell death induced by all 4 molecules by over 50%.
Conclusion:
ANAVEX2-73, which like DM is a S-1R and NMDAR antagonist but differs in other activities, protects OL from cytotoxic mechanisms involved in pathogenesis of MS lesions. Studies to determine the relative roles of S-1R agonism, NMDAR antagonism and muscarinic activities are objectives for future studies. ANAVEX2-73 and DM are small molecules that enter the central nervous system and thus have potential to provide protection of OL in MS.
http://www.nationalmssociety.org/For-Professionals/Clinical-Care/Managing-MS/Disease-Modification#section-5
The 003 study is aimed squarely at long term saftey. AVXL will uproot the entire spectrum of CNSD therapies if the trend stays positive.
§
$INNV
15:53 900,000 .1349...rightontime
Good day of loading. Should have set higher and taken more. Touche' who got the 80KK @ .139...shysted me!
Hopefully the co will double-down on some dilution shares to feed in.
§
That's the idea. I owned ISRG at $7...5 splits ago...
§
No, not at the moment. I said I have a 4.99% investment interest.
That would be real close to 25%, or 9.5MM based on 38MM outstanding.
They stuck it in the Degus and said, "BOY HOWDY!" :-0
§
Total insider, tute and group holdings = 23.8%
As I figure it. Up from 21.3% last month.
Your 16% would be Uncle Tom, Missling, tutes, et al.
Add the rest for me and other groups. I don't know about FB group, may take it to ~24%?
I hold a 4.99% total interest until the drug fails.
§
23.8% §
There's the 15s! §
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
On June 3, 2016, American CareSource Holdings, Inc. borrowed $1,638,888.50 from three of the Company’s directors, John Pappajohn, Mark Oman, and Matt Kinley. The loan is evidenced by promissory notes issued to each such director, which bear interest at 6% per annum. Interest-only payments are due and payable under the promissory notes on the first day of each calendar month after the date of issuance, and all principal and accrued but unpaid interest are due and payable 18 months after the date of issuance. The description of the promissory notes in this Current Report on Form 8-K does not purport to be complete and is qualified by reference to the full text of the form of promissory note which is attached hereto as Exhibit 10.1 and incorporated herein by reference.
§
AF called it!
"There is nothing this drug cannot do! Bravo, Chris Missling!"
Spot-on...should we congrat him?
§
...due to the IVV inclusion...§
I think we'll see a declaration and tender offer when he reaches 51%. He's making sure to report the indirect holdings, and will prolly come up with more in a gifted transaction.
§